Charles River Laboratories (CRL) said Wednesday it plans to undertake a strategic review of its business including an assessment of alternatives to enhance long-term stockholder value.
The pharmaceutical company also said it has entered into a cooperation agreement with Elliott Investment Management, its largest shareholder, under which the activist investor assented to customary standstill, voting, confidentiality, and other provisions.
The company said it has agreed to appoint four new directors who will join the board after the shareholders' annual meeting on May 20: Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves.
After the new director appointments, the board will consist of 11 members, nine of whom will be independent, the company said.
Price: 141.90, Change: +26.49, Percent Change: +22.95
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。